AroCell Management

Management criteria checks 0/4

AroCell's CEO is Anders Hultman, appointed in Jan 2021, has a tenure of 3.33 years. directly owns 0.49% of the company’s shares, worth €41.36K. The average tenure of the management team and the board of directors is 0.8 years and 2.3 years respectively.

Key information

Anders Hultman

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	3.3yrs
CEO ownership	0.5%
Management average tenure	less than a year
Board average tenure	2.3yrs

Recent management updates

Recent updates

CEO

Anders Hultman (49 yo)

3.3yrs

Tenure

Mr. Anders Hultman, B.Sc., has been Chief Executive Officer at AroCell AB (publ) since January 11, 2021. Mr. Hultman served as Chief Financial Officer at AroCell AB (publ) since December 2018 until January...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Anders Hultman	Chief Executive Officer	3.3yrs	no data	0.49% SEK 41.4k
Lars Jakobsson	Acting Chief Financial Officer	less than a year	no data	no data
Jonas Söderholm	Global Medical Lead	no data	no data	no data
Gustav Sten	Chief Operating Officer	2.4yrs	no data	0.036% SEK 3.1k
Kiran Jagarlamudi	Chief Scientific Officer	1.3yrs	no data	0.0069% SEK 587.9
Gunnar Wahlberg	Chief Sales Officer	less than a year	no data	0.065% SEK 5.5k
Marie Torstensson	Chief Marketing Officer	less than a year	no data	0.033% SEK 2.8k
Ellen Dittberner	Chief Finance Officer (Leave of Absence)	less than a year	no data	no data
Tina Yang	Chief Quality Officer	2.3yrs	no data	0.0033% SEK 279.0

0.8yrs

Average Tenure

Experienced Management: 80R's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Charlotta Ljungqvist	Independent Director	3yrs	no data	no data
Johan Haggblad	Independent Chairman	2yrs	no data	no data
Clas Runnberg	Independent Director	1.3yrs	no data	no data
Staffan Eriksson	Member of Advisory Board	3.2yrs	no data	no data
Max Pihlqvist	Director	2.3yrs	no data	0.93% SEK 78.8k
Eva Nordström	Independent Director	4.3yrs	no data	0.021% SEK 1.8k
Agneta Alm	Independent Director	2yrs	no data	no data

2.3yrs

Average Tenure

60.5yo

Average Age

Experienced Board: 80R's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.

AroCell Management

Management criteria checks 0/4

Key information

Recent management updates

AroCell AB (publ), Annual General Meeting, May 22, 2024

AroCell AB (publ) Announces Chief Financial Officer Changes

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new directors

AroCell AB (publ) Announces CFO Changes

Recent updates

AroCell AB (publ), Annual General Meeting, May 22, 2024

AroCell AB (publ) to Report Fiscal Year 2024 Results on Feb 19, 2025

Now 20% undervalued after recent price drop

Now 21% undervalued after recent price drop

Full year 2023 earnings released: kr0.26 loss per share (vs kr0.27 loss in FY 2022)

AroCell AB (publ) to Report Q3, 2024 Results on Oct 24, 2024

AroCell AB (publ) Announces Chief Financial Officer Changes

Now 24% undervalued after recent price drop

Third quarter 2023 earnings released: kr0.06 loss per share (vs kr0.048 loss in 3Q 2022)

New major risk - Market cap size

AroCell AB (Publ) Announces New Study Highlights the Clinical Significance of TK1 SA for Early Detection of Ovarian Cancer

New major risk - Market cap size

Second quarter 2023 earnings released: kr0.067 loss per share (vs kr0.069 loss in 2Q 2022)

First quarter 2023 earnings released: kr0.06 loss per share (vs kr0.091 loss in 1Q 2022)

Full year 2022 earnings released: kr0.28 loss per share (vs kr0.53 loss in FY 2021)

High number of new and inexperienced directors

Third quarter 2022 earnings released: kr0.05 loss per share (vs kr0.15 loss in 3Q 2021)

Second quarter 2022 earnings released: kr0.07 loss per share (vs kr0.089 loss in 2Q 2021)

AroCell AB (publ) to Report Fiscal Year 2022 Results on Feb 23, 2023

AroCell Announced UBC® Rapid is Now Verified for Use on New Instrument

High number of new and inexperienced directors

AroCell AB (publ) Announces New Clinical Study to Broaden the Use of TUBEX® TF on the African Market

First quarter 2022 earnings released: kr0.09 loss per share (vs kr0.08 loss in 1Q 2021)

High number of new directors

AroCell AB (publ) Announces CFO Changes

Full year 2021 earnings released: kr0.54 loss per share (vs kr0.33 loss in FY 2020)

High number of new directors

AroCell AB (publ), Annual General Meeting, May 24, 2022

First quarter 2021 earnings released: kr0.08 loss per share (vs kr0.086 loss in 1Q 2020)

AroCell AB (publ) (OM:AROC) agreed to acquire IDL Biotech AB (publ) for approximately SEK 240 million.

Chief Commercial Officer has left the company

Full year 2020 earnings released: kr0.33 loss per share (vs kr0.53 loss in FY 2019)

AroCell AB (publ), Annual General Meeting, May 06, 2021

New 90-day high: €0.30

New 90-day high: €0.29

AroCell AB (publ) Appoints Gunnar Steineck as Chief Medical Officer

AroCell AB (publ) Appoints Anders Hultman as CEO

New 90-day low: €0.26

Earnings released

New 90-day high - €0.33

CEO

Tenure

Leadership Team

Average Tenure

Board Members

Average Tenure

Average Age